title: Comparison of troponin I and N-terminal-pro B-type natriuretic peptide for risk stratification in patients with pulmonary embolism.
abstract: OBJECTIVE
  We compared the usefulness of plasma N-terminal-pro B-type natriuretic peptide and troponin I levels for risk stratification of patients with pulmonary embolism.
  
  
  METHODS
  This was a prospective study performed in an emergency department. N-terminal-B-type natriuretic peptide assay and troponin I were performed blindly at admission in patients with pulmonary embolism confirmed by imaging tests. A complicated pulmonary embolism was defined as any of the following: death, cardiopulmonary resuscitation, requirement for mechanical ventilation, use of pressors, thrombolysis, surgical embolectomy or admission in an intensive care unit.
  
  
  RESULTS
  Sixty patients (mean age+/-standard deviation of 72+/-15 years) were included. Seventeen (28%) patients had adverse events: all were admitted in intensive care unit, one was treated with surgical embolectomy and one with thrombolysis, and three died. The median N-terminal-pro B-type natriuretic peptide level (95% confidence interval) was higher in the group of patients with complicated pulmonary embolism, 4086 pg/ml (505-8998) versus 352 pg/ml (179-662), respectively (P<0.05). The mean value of troponin I was similar in the complicated pulmonary embolism group, 0.09+/-0.17 microg/l versus 0.08+/-0.41 microg/l, respectively (P=0.93). The best threshold value of N-terminal-pro B-type natriuretic peptide was 1000 pg/ml, and the receiver operating characteristic curve demonstrated that N-terminal-pro B-type natriuretic peptide significantly predicted the complicated pulmonary embolism with an area under the receiver operative curve of 0.72 (0.58-0.83) (P<0.05), whereas troponin I did not [area under the receiver operative curve of 0.58 (0.42-0.71)].
  
  
  CONCLUSIONS
  Unlike troponin I, N-terminal-pro B-type natriuretic peptide may be an accurate marker of in-hospital complication after pulmonary embolism.
authors.affiliation: Department of Emergency Medicine and Surgery, Centre Hospitalo-Universitaire (CHU) Pitié-Salpêtrière Hospital, Assistance-Publique Hôpitaux de Paris (AP-HP), Université Pierre et Marie Curie, Paris, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Maziere
authors.forename: Sophie
authors.initials: S
authors.lastname: Birolleau
authors.forename: Sassi
authors.initials: S
authors.lastname: Medimagh
authors.forename: Martine
authors.initials: M
authors.lastname: Arthaud
authors.forename: Mohamed
authors.initials: M
authors.lastname: Bennaceur
authors.forename: Bruno
authors.initials: B
authors.lastname: Riou
authors.forename: Patrick
authors.initials: P
authors.lastname: Ray
mesh_terms: D000117:Acetylglucosamine / Q000031:analogs & derivatives* / Q000097:blood; D000368:Aged; D015415:Biomarkers; D004636:Emergency Service, Hospital; D005260:Female; D005602:France; D006801:Humans; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D011655:Pulmonary Embolism / Q000097:blood* / Q000150:complications / Q000628:therapy; D012307:Risk Factors; D019210:Troponin I / Q000097:blood*
chemical_list: D015415:Biomarkers; C448219:N-trichloroacetyl-glucosamine; D019210:Troponin I; D000117:Acetylglucosamine